Networks
NIAID participates in or funds many different consortia, clinical trial programs, networks, and research collaborations that help to move science forward. These are listed here, with new ones added all the time. Use the Search for Networks field to narrow your search.
Accelerating Medicines Partnership Rheumatoid Arthritis and Lupus Network (AMP)
The Accelerating Medicines Partnership is a public-private collaboration among the National Institutes of Health, pharmaceutical companies, and non-profit organizations.
Accessing Clinical Data
NIAID Clinical Trials Data Repository, AccessClinicalData@NIAID, is an NIAID cloud-based, secure data platform that enables sharing of and access to reports and data sets from NIAID COVID-19 and other sponsored clinical trials for the basic and clinical research community.
Adjuvant Development Program
This program aims to advance novel vaccine adjuvants toward licensure for human use. The program supports the optimization of adjuvant candidates; vaccine formulation and preclinical adjuvant pharmacology, toxicity, and efficacy studies.
AIDS Clinical Trials Group (ACTG)
The ACTG established and supports the largest Network of expert clinical and translational investigators and therapeutic clinical trials units in the world, including sites in resource-limited countries. These investigators and units serve as the major resource for HIV/AIDS research, treatment, care, and training/education in their communities.
Antibacterial Resistance Leadership Group (ARLG)
In 2013, NIAID launched the Antibacterial Resistance Leadership Group (ARLG), a major clinical effort to address antibacterial resistance (AR).
Asthma and Allergic Diseases Cooperative Research Centers (AADCRCs)
The AADCRC program is the cornerstone of NIAID efforts to promote multidisciplinary basic and clinical research on the immunological basis, pathobiology, diagnosis, treatment, and prevention of asthma and allergic diseases.
Atopic Dermatitis Research Network (ADRN)
The Atopic Dermatitis Research Network is a consortium of academic medical centers that conduct clinical research studies in an attempt to learn more about skin infections associated with atopic dermatitis.
Autoimmunity Centers of Excellence (ACE)
The ACEs conduct collaborative basic and clinical research on autoimmune diseases. Close interaction between clinicians and basic researchers accelerates the discovery, development, and translation of therapies for autoimmune diseases from the lab to use in the clinic.
Biocontainment Research Facilities
The National Biocontainment Laboratories (NBLs) and Regional Biocontainment Laboratories (RBLs) provide BSL4/3/2 and BSL3/2 biocontainment facilities, respectively, for research on biodefense and emerging infectious disease agents.
Bioinformatics and Computational Biosciences Branch
The Bioinformatics and Computational Biosciences Branch (BCBB) drives innovation in biomedical informatics at the NIAID for global health clinicians and researchers by fostering a pipeline of products, platforms, and solutions.
Bioinformatics Resource Centers
The Bioinformatics Resource Centers (BRCs) for Infectious Diseases program was initiated in 2004 with the main objective of providing public access to computational platforms and analysis tools that enable collecting, archiving, updating, and integrating a variety of genomics and related research data relevant to infectious diseases, and pathogens and their interaction with hosts
Center for Advanced Tissue Imaging (CAT-I)
The Center for Advanced Tissue Imaging (CAT-I) is an NIAID and NCI supported effort involving collaborative studies between experts in the Laboratory of Immune System Biology, DIR, NIAID and investigators in the DIR, NIAID and CCR, NCI.
Center for HIV/AIDS Vaccine Immunology & Immunogen Discovery (CHAVI-ID)
CHAVI-ID are two consortiums established by NIAID to undertake the immunologic research required to tackle the major scientific obstacles in the development of an effective HIV vaccine. The two seven-year awards were made in 2012, one to Duke University and a second to The Scripps Research Institute.
Center for Infectious Disease Imaging (CIDI)
CIDI is a partnership between NIAID and Radiology and Imaging Sciences at the National Institutes of Health Clinical Center. It was established to perform basic science, translational, and clinical research on the imaging features of infectious disease.
Centers for AIDS Research (CFAR)
The Centers for AIDS Research (CFAR) program at the National Institutes of Health provides administrative and shared research support to synergistically enhance and coordinate high quality AIDS research projects. CFARs accomplish this through core facilities that provide expertise, resources, and services not otherwise readily obtained through more traditional funding mechanisms.
Centers for HIV Structural Biology
The Centers for HIV Structural Biology, established in 2007, integrate a variety of techniques from structural biology, biochemistry and cell biology to capture in unprecedented detail the three-dimensional structures of HIV components bound to human cellular components, such as proteins or DNA.
Centers for Medical Countermeasures Against Radiation Consortium
The Medical Countermeasures against Radiation Consortium (CMCRC) is a network of national research centers working together to develop effective and comprehensive medical countermeasures applicable to all subsets of the civilian population in the event of radiological or nuclear emergencies.
Centers for Research in Emerging Infectious Diseases (CREID)
The global network involves multidisciplinary investigations into how and where viruses and other pathogens can emerge from wildlife and spillover to cause disease in people. Research is led by 10 Centers and one Coordinating Center and will involve collaborations with peer institutions in the United States and 28 other countries.
Centers of Excellence for Influenza Research and Surveillance (CEIRS)
The National Institute of Allergy and Infectious Diseases (NIAID) Centers of Excellence for Influenza Research and Surveillance (CEIRS) program is an integrated network of centers designed to bring together multidisciplinary teams of researchers that perform surveillance related research integrated with research on host immune response, viral pathogenesis, and the factors that control the emerg
Centers of Excellence for Translational Research (CETR)
In 2014, NIAID established the Centers of Excellence for Translational Research (CETR) program. Supported translational activities will range from very early discovery-based efforts to late-stage preclinical development.
Clinical Islet Transplantation Consortium (CITC)
The Clinical Islet Transplantation Consortium is a network of clinical centers and a data coordinating center established in 2004 to conduct studies of islet transplantation in patients with type 1 diabetes.
Clinical Trials in Organ Transplantation (CTOT)
The Clinical Trials in Organ Transplantation (CTOT) program is an investigative consortium that conducts clinical and associated mechanistic studies to improve outcomes for transplant recipients.
Clinical Trials in Organ Transplantation in Children (CTOT-C)
The Clinical Trials in Organ Transplantation in Children (CTOT-C) program focuses on the specific challenges associated with pediatric organ transplantation. This program is a continuation of the first NIAID pediatric transplantation clinical trial consortium, the Cooperative Clinical Trials in Pediatric Transplantation program.
Collaborative Influenza Vaccine Innovation Centers (CIVICs)
CIVICs is a network of research centers that will work together in a coordinated, multidisciplinary effort to develop more durable, broadly protective and longer-lasting influenza vaccines. The CIVICs program will include three Vaccine Centers, one Vaccine Manufacturing and Toxicology Core, two Clinical Cores, and one Statistical, Data Management, and Coordination Center (SDMCC).
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)
The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) global partnership was created to help address the threat of antibiotic resistance.